GVAG
NGEN

Great Valley Advisor Group’s NervGen Pharma NGEN Stock Holding History

Great Valley Advisor Group’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.1K Buy
35,500
+14,500
+69% +$45K ﹤0.01% 1024
2026
Q1 		$79.2K Buy
+21,000
New +$91K ﹤0.01% 981

Other funds holding NGEN

EAM
Empery Asset Management New York $86.5M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Great Valley Advisor Group's NGEN Position: Q2 2026 in Review

Great Valley Advisor Group increased its NervGen Pharma (NGEN) stake by 69% in Q2 2026, buying an estimated $45K and bringing the position to 35,500 shares worth $73.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1024.

Great Valley Advisor Group first reported a position in NGEN in Q1 2026 and has held it in 2 quarters since. The position peaked at $79.2K in Q1 2026. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • Great Valley Advisor Group held 35,500 shares of NervGen Pharma worth $73.1K as of Q2 2026.
  • Great Valley Advisor Group bought 14,500 NervGen Pharma shares in Q2 2026, an estimated $45K.
  • NervGen Pharma made up ﹤0.01% of Great Valley Advisor Group's portfolio in Q2 2026, its #1024 holding.
  • Great Valley Advisor Group first reported a position in NervGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • Great Valley Advisor Group's NervGen Pharma position peaked at $79.2K in Q1 2026.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Great Valley Advisor Group's 13F filing for Q2 2026, filed 10 Aug 2026.